Charles Schwab Investment Management Inc. increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,987,656 shares of the medical device company's stock after purchasing an additional 162,450 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.76% of DexCom worth $204,027,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently modified their holdings of the company. Golden State Wealth Management LLC increased its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the period. Optiver Holding B.V. purchased a new position in shares of DexCom during the fourth quarter valued at about $33,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the fourth quarter valued at about $38,000. Alpine Bank Wealth Management purchased a new position in shares of DexCom during the first quarter valued at about $40,000. Finally, Private Trust Co. NA increased its position in shares of DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.
DexCom Stock Up 3.2%
DXCM opened at $78.86 on Friday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The stock has a market capitalization of $30.92 billion, a price-to-earnings ratio of 54.76, a PEG ratio of 1.65 and a beta of 1.43. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average price of $83.68 and a 200-day moving average price of $80.32.
DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The firm's revenue was up 15.2% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.
Insider Activity
In other news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director directly owned 33,411 shares of the company's stock, valued at $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is currently owned by company insiders.
Analyst Ratings Changes
DXCM has been the topic of several research analyst reports. Morgan Stanley boosted their price target on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. The Goldman Sachs Group started coverage on shares of DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Citigroup reissued a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Finally, Oppenheimer boosted their price objective on shares of DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $99.89.
Get Our Latest Stock Analysis on DXCM
DexCom Company Profile
(
Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.